Drugs Requiring Medical Necessity Review (product-specific prior authorization list)
Customize your policy alerts
Sign up for Cigna Policy 1602 alerts
Get alerted when Policy 1602 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity review requirements and preferred product step requirements for various drugs under Cigna-administered health benefit plans; affects providers submitting prior authorization requests and Cigna medical directors making coverage determinations.
Added preferred product step requirement for Orlynvah, Brynovin, and Lasix Onyu.
Added preferred product step requirement for opium tincture 10 mg/mL, Ertaczo, Exelderm cream and solution, Jublia, Luzu, oxiconazole nitrate 1% cream, Oxistat cream and lotion, sulconazole nitrate 1% cream and solution, Xolegel, Bevespi Aerosphere, Duaklir Pressair, Ryaltris, Omnaris, Qnasl, Qnasl Children's, Xhance, Zetonna, tavaborole 5% topical solution, miconazole-zinc oxide-petrolatum ointment, and Vusion.
Updated preferred product step requirement for Zoryve 0.3% cream, Zoryve foam, Firvanq, and vancomycin 25 mg/mL oral solution (authorized generic of Firvanq).
Documentation wording changed to require that documentation is 'required where noted in the criteria' and that all documentation must include patient-specific identifying information.
Updated preferred product step requirement for Furoscix, dihydroergotamine mesylate nasal spray (generic Migranal), Trudhesa, Lotemax, Vtama, ArmonAir DigiHaler, Arnuity Ellipta, Flovent Diskus, Flovent HFA, and certain authorized generics.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.